Valneva to Present on its Chikungunya Vaccine Candidate and Host a Roundtable at the 23rd World Vaccine Congress in Washington D.C.GlobeNewsWire • 03/30/23
Valneva Q4: Resilient Pipeline And Partnership With Pfizer, Reinforcing A Promising FutureSeeking Alpha • 03/30/23
Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001GlobeNewsWire • 03/02/23
Valneva SE: Underfollowed French Biotech, 2 Interesting Vaccine Approvals Expected In 2023Seeking Alpha • 02/26/23
FDA Accepts Valneva's Chikungunya Vaccine License Application for Priority ReviewGlobeNewsWire • 02/20/23
Valneva Shares Topple As It Hits Ethics Roadblock With Pfizer In Lyme Disease TestInvestors Business Daily • 02/17/23
Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15GlobeNewsWire • 02/17/23
Valneva Reports Full Year 2022 Revenue and Cash, Provides First 2023 GuidanceGlobeNewsWire • 02/16/23
Valneva Completes Enrollment for Adolescent Phase 3 Trial of Single-Shot Chikungunya Vaccine CandidateGlobeNewsWire • 02/14/23
Valneva Reports Further Heterologous Booster Data for its inactivated COVID-19 vaccineGlobeNewsWire • 12/30/22
Valneva Completes BLA Submission to U.S. FDA for its Single-Shot Chikungunya Vaccine CandidateGlobeNewsWire • 12/23/22
Valneva (VALN) Up on Antibody Persistence Data on Chikungunya JabZacks Investment Research • 12/06/22
Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya Vaccine CandidateGlobeNewsWire • 12/05/22
Will A Pfizer-Partnered Vaccine Help Valneva Stock Buck Its Recent Downtrend?Investors Business Daily • 12/01/22
Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine CandidateGlobeNewsWire • 12/01/22
Wall Street Analysts See a 65% Upside in Valneva SE Sponsored ADR (VALN): Can the Stock Really Move This High?Zacks Investment Research • 11/16/22